Literature DB >> 11589520

Tissue uptake of ketamine and norketamine enantiomers in the rat: indirect evidence for extrahepatic metabolic inversion.

S R Edwards1, L E Mather.   

Abstract

Ketamine, used clinically as an intravenous analgetic and dissociative anaesthetic agent, is a racemate with both pharmacokinetic and pharmacodynamic enantioselectivity. S-ketamine has been found have a higher clearance and greater potency than R-ketamine as well as a greater therapeutic index. We performed a study in rats with two complementary paradigms: (i) constant rate "washin" infusion until fatal, (ii) brief infusion then "washout". These, respectively, allowed examination of ketamine and norketamine serial plasma enantiomer concentrations and tissue distribution at maximal and minimal drug effects. Both paradigms found plasma concentrations of R-ketamine>S-ketamine; however, tissue distribution coefficients for S-ketamine>R-ketamine. For paradigm (i), plasma concentrations of R-norketamine>S-norketamine; for paradigm (ii), R-norketamine>>S-norketamine initially, but S-norketamine>>R-norketamine later. Comparison of distribution coefficients of ketamine and norketamine enantiomers for the two paradigms provided indirect evidence for metabolic inversion. During washin, when circulating concentrations of ketamine enantiomers were high, uptake and metabolism occurred predominantly in the kidney and to a lesser extent in liver, lung and gut, with formation of R-norketamine by a (presumed) first-order process predominating. However, following washout, when circulating concentrations of ketamine enantiomers were low, uptake and metabolism was dominated by the kidney and gut. Under these conditions inversion of R- to S-ketamine appeared to predominate with subsequent metabolism to S-norketamine by (presumed) zero-order processes. In summary, different profiles for the uptake and metabolism of ketamine enantiomers were apparent following constant rate washin, and brief infusion washout, paradigms with i.v. rac-ketamine. Uptake into most tissues, and metabolism in some tissues, was enantioselective.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11589520     DOI: 10.1016/s0024-3205(01)01287-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  12 in total

Review 1.  Ketamine enantiomers in the rapid and sustained antidepressant effects.

Authors:  John Muller; Sahana Pentyala; James Dilger; Srinivas Pentyala
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-10

2.  Antinociceptive effects, metabolism and disposition of ketamine in ponies under target-controlled drug infusion.

Authors:  M Knobloch; C J Portier; O L Levionnois; R Theurillat; W Thormann; C Spadavecchia; M Mevissen
Journal:  Toxicol Appl Pharmacol       Date:  2006-07-03       Impact factor: 4.219

3.  Sampling Site Has a Critical Impact on Physiologically Based Pharmacokinetic Modeling.

Authors:  Weize Huang; Nina Isoherranen
Journal:  J Pharmacol Exp Ther       Date:  2019-10-11       Impact factor: 4.030

4.  Population Pharmacokinetic Modeling of Remifentanil in Infants with Unrepaired Tetralogy of Fallot.

Authors:  Jing Chang; Yang Shen; Yue Huang; Ying Sun; Mei-Hua Cai; Jing Niu; Li-Ming Zhang; Ji-Jian Zheng; Ma-Zhong Zhang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-02       Impact factor: 2.441

Review 5.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

6.  Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: Preliminary findings from a three-way randomized, crossover study.

Authors:  Chui Chong; Stephan A Schug; Madhu Page-Sharp; Barry Jenkins; Kenneth F Ilett
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

7.  Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings).

Authors:  Georges Mion; Thierry Villevieille
Journal:  CNS Neurosci Ther       Date:  2013-04-10       Impact factor: 5.243

Review 8.  Role of Ketamine in the Treatment of Psychiatric Disorders.

Authors:  Sahar Derakhshanian; Maxine Zhou; Alexander Rath; Rachel Barlow; Sarah Bertrand; Caroline DeGraw; Christopher Lee; Jamal Hasoon; Alan D Kaye
Journal:  Health Psychol Res       Date:  2021-06-22

9.  Alteration in the plasma concentration of a DAAO inhibitor, 3-methylpyrazole-5-carboxylic acid, in the ketamine-treated rats and the influence on the pharmacokinetics of plasma D-tryptophan.

Authors:  Naomi Haruta; Hideaki Iizuka; Kana Ishii; Shunsuke Yoshihara; Hideaki Ichiba; Takeshi Fukushima
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2011       Impact factor: 3.493

10.  Physiologically based pharmacokinetic modeling of arterial - antecubital vein concentration difference.

Authors:  David G Levitt
Journal:  BMC Clin Pharmacol       Date:  2004-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.